CNS Pharmaceuticals (CNSP) vs Soligenix (SNGX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
CNS Pharmaceuticals is the larger company by market cap ($7.8 million vs $7.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CNSP | SNGX |
|---|---|---|
| Share price | $5.35 | $0.3466 |
| Market cap | $7.82M | $7.54M |
| 1-day change | -1.47% | -1.95% |
| EPS (TTM) | $-17.90 | $-0.79 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $10.54 | $1.80 |
| 52-week low | $1.90 | $0.28 |
| Distance from 52-week high | -49.24% | -80.74% |
| Analyst consensus | none | none |
| Avg. price target upside | +86.92% | +298.15% |
| Average volume | 6.40K | 249.87K |
| Shares outstanding | 1.46M | 21.77M |
| Employees | 8 | 13 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About CNS Pharmaceuticals
CNSP stock →CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of therapies for neurology and oncology diseases in the United States. It develops TPI 287, an investigational chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma, metastatic breast cancer with brain metastases, non-small cell lung cancer, castration-resistant prostate cancer, and neuroblastoma; and Berubicin, an investigational anthracycline chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma and brain tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 8 employees
About Soligenix
SNGX stock →Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions.
Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees
CNSP vs SNGX FAQ
Which is bigger, CNS Pharmaceuticals or Soligenix?
CNS Pharmaceuticals (CNSP) is larger, with a market capitalization of $7.82M compared with $7.54M for Soligenix (SNGX).
Are CNS Pharmaceuticals and Soligenix in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.